A Phase 1 interventional study of ZT002 injection, metformin, warfarin and ZT002 injection, rosuvastatin, digoxin in Overweight,Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing metformin in Obesity — 15 open to participants now, 17 under way, 3 of them phase 3. Metformin · Obesity.
Among the 81 studies testing metformin in Obesity, this one is the 42nd largest by planned enrollment, is one of 5 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 8 of the 16 other live ones, and was the 77th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →15 of the 81 studies testing metformin in Obesity are open now, in 9 countries. Recruiting first, the newest first:
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Riphah International University · Sites in Pakistan
Healthy volunteers
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 18–45
Fudan University · Sites in China
Ages 60–75
University Of Nigeria Teaching Hospital · Sites in Nigeria
Ages 20–59
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 13 · Phase 4 29
First in 1996; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 62 across the 81 interventional studies. Of the 55 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 81 have an industry lead sponsor. The 10 most frequent:
Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd: 2 open now, 7 under way, 1 of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, this one is the 6th largest by planned enrollment, is one of 6 that started in 2026, is one of 6 in phase 1, and was the 7th registered.
Beijing QL Biopharmaceutical Co.,Ltd’s Obesity studies by the year they started, since 2023.
8 of the studies testing metformin in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07297290Phase 3University Of Nigeria Teaching HospitalEffect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI) | 2027-03-31 |
| NCT07622290Phase 3Prof Ibrahim JanahiMetformin Treatment for Children With Obesity-associated Asthma | 2027-08 |
| NCT07550816Beijing QL Biopharmaceutical Co.,LtdDrug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | 2026-12-05 |
| NCT06273072Johns Hopkins UniversityMetformin IN Asthma for Overweight and Obese Individuals (MINA) | 2026-12-31 |
| NCT05744479Centre for Addiction and Mental HealthMetformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability | 2027-03-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 81 studies testing metformin in Obesity, from their registry updates:
Among Beijing QL Biopharmaceutical Co.,Ltd’s 10 in Obesity:
This tab as a report to print or save as PDF → With an account.
ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin and digoxin. The study will include obese and overweight but otherwise healthy participants aged 18 - 45.
The study consists of two cohorts. Each participant can only join one of the cohorts.
Cohort 1 evaluates the impact of ZT002 on the PK of metformin at steady state and on the PK of a single dose of warfarin. Participants are screened within 2 weeks before study drug administration. In the first period, metformin is given twice daily for 3.5 days and warfarin is given as a single dose without ZT002. In the second period, metformin and warfarin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.
Cohort 2 evaluates the impact of ZT002 on the PK of single doses of rosuvastatin and digoxin. Participants are screened within 2 weeks before study drug administration. In the first period, rosuvastatin and digoxin are given as single doses without ZT002. In the second period, rosuvastatin and digoxin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's planned enrollment of 60 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Exclusion Criteria:
Exclusion criteria only applicable to Cohort 1:
Exclusion criteria only applicable to Cohort 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZT002 injection, metformin, warfarin
Drug: ZT002 injection, metformin, warfarin
ZT002 injection, rosuvastatin, digoxin
Drug: ZT002 injection, rosuvastatin, digoxin
Drug pages: ZT002 · Metformin · Warfarin
Drug: metformin Participants will receive metformin twice daily for 3.5 days in both periods Drug: warfarin Participants will receive a single dose of warfarin in both periods Drug: ZT002 Participants will receive multiple doses of ZT002 in the second period
Drug pages: ZT002 · Rosuvastatin · Digoxin
Drug: rosuvastatin Participants will receive a single dose of rosuvastatin in both periods Drug: digoxin Participants will receive a single dose of digoxin in both periods Drug: ZT002 Participants will receive multiple doses of ZT002 in the second period
Area under the concentration-time curve of metformin within dosing interval (12 hours) at steady state
Time frame: From Day 4 to Day 5, from Day 112 to Day 113
Area under the concentration-time curve of S-warfarin from time zero to infinity after single-dose administration
Time frame: From Day 6 to Day 13, from Day 126 to Day 133
Area under the concentration-time curve of R-warfarin from time zero to infinity after single-dose administration
Time frame: From Day 6 to Day 13, from Day 126 to Day 133
Area under the concentration-time curve of rosuvastatin from time zero to infinity after single-dose administration
Time frame: From Day 1 to Day 5, from Day 111 to Day 115
Area under the concentration-time curve of digoxin from time zero to infinity after single-dose administration
Time frame: From Day 5 to Day 12, from Day 125 to Day 132
Maximal observed concentration of metformin at steady state
Time frame: From Day 4 to Day 5, from Day 112 to Day 113
Maximal observed concentration of S-warfarin after single-dose administration
Time frame: From Day 6 to Day 13, from Day 126 to Day 133
Maximal observed concentration of R-warfarin after single-dose administration
Time frame: From Day 6 to Day 13, from Day 126 to Day 133
Maximal observed concentration of rosuvastatin after single-dose administration
Time frame: From Day 1 to Day 5, from Day 111 to Day 115
Maximal observed concentration of digoxin after single-dose administration
Time frame: From Day 5 to Day 12, from Day 125 to Day 132
Area under the INR-time curve after single-dose warfarin administration
Time frame: From Day 6 to Day 13, from Day 126 to Day 133
Maximal INR after single-dose warfarin administration
Time frame: From Day 6 to Day 13, from Day 126 to Day 133
Percentage change in body weight
Time frame: Day 13 and Day 133 in Cohort 1, Day 12 and Day 132 in Cohort 2
Proportion of participants with positive anti-drug antibody against ZT002
Time frame: From Day 13 to Day 167 in Cohort 1, from Day 12 to Day 166 in Cohort 2
Proportion of participants with treatment-emergent adverse events
Time frame: From baseline to Day 167 in Cohort 1, from baseline to Day 166 in Cohort 2
Proportion of participants with serious adverse events
Time frame: From baseline to Day 167 in Cohort 1, from baseline to Day 166 in Cohort 2
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 6 months is below that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ZT002 · Metformin · Warfarin · Rosuvastatin · Digoxin
Beijing QL Biopharmaceutical Co.,Ltd →